[Skip to content]

Print this page
.

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120121-140141-160161-180181-200201-220221-240;  241-260 261-280; 281-300; 301-320; 321-340 ; 341-360; 381-400; 401-420; 421-440; 441-460; 461-480

 

NICE TAs 481-500

REF

TITLE                

DHFT Formulary link 

East Midlands Cancer Network link (cancer drugs only) 

TA 481

Immunosuppressive therapy for kidney transplant in adults


 
TA 482

Immunosuppressive therapy for kidney transplant in children and young people

   
TA 483

Nivolumab for previously treated squamous non-small-cell lung cancer

 

Link to cancer network protocol

TA 484

Nivolumab for previously treated non-squamous non-small-cell lung cancer

 

Link to cancer network protocol

TA 485

Sarilumab for moderate to severe rheumatoid arthritis

10.1.2 - 10.1.4 Corticosteroids, rheumatic disease suppressants, gout 

 
TA 486

Aflibercept for treating choroidal neovascularisation

   
TA 487

Venetoclax for treating chronic lymphocytic leukaemia

 

Link to cancer network protocol

TA 488 

Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours

   
TA 489

Vismodegib for treating basal cell carcinoma

   
TA 490

Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy

 

Link to cancer network protocol

TA 491

Ibrutinib for treating Waldenström’s macroglobulinaemia

 

Link to cancer network protocol

TA 492

Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

   
TA 493

Cladribine tablets for treating relapsing–remitting multiple sclerosis

   
TA 494

Naltrexone–bupropion for managing overweight and obesity

Not recommended by NICE


TA 495

Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

   
TA 496

Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer